ARS Pharmaceuticals, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
ARS Pharmaceuticals, Inc. (SPRY) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $11.20 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-13
- ARS Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $11.47, a 6.90% increase year-over-year.
- ARS Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $10.73, a 92.29% increase year-over-year.
- ARS Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $5.58, a 32.45% decline year-over-year.
- ARS Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $8.26, a 70.31% increase year-over-year.
- ARS Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $11.63, a 39.11% increase from fiscal 2024.
- ARS Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $8.36, a 4.11% increase from fiscal 2023.
- ARS Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $8.03, a 435.33% increase from fiscal 2022.
- ARS Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $1.50.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.20 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | $11.47 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | $11.63 10-K · filed 2026-03-09 | |||
| 2025-09-30 | $11.67 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $11.54 10-Q · filed 2025-08-13 | |||
| 2025-03-31 | $10.73 10-Q · filed 2025-05-14 | |||
| 2024-12-31 | $8.36 10-K · filed 2025-03-20 | |||
| 2024-09-30 | $7.16 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $5.81 10-Q · filed 2024-08-06 | |||
| 2024-03-31 | $5.58 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $8.03 10-K · filed 2024-03-21 | |||
| 2023-09-30 | $8.03 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $8.03 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $8.26 10-Q · filed 2023-05-15 | |||
| 2022-12-31 | $1.50 10-K · filed 2023-03-23 | |||
| 2022-09-30 | $4.20 10-Q · filed 2022-11-02 | |||
| 2022-06-30 | $4.20 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | $4.85 10-Q · filed 2022-05-12 | |||
| 2021-09-30 | $36.64 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | $39.02 10-Q · filed 2021-08-12 | |||
| 2021-03-31 | $48.03 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |